Search Result

Results for "

TAMs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TAM Receptor (8) ADC Antibody (1) ADC Cytotoxin (4) Akt (1) Apoptosis (4) Autophagy (2) Bacterial (1) c-Fms (6) c-Kit (1) c-Met/HGFR (1) Cytochrome P450 (3) Drug Intermediate (3) Drug Metabolite (3) Drug-Linker Conjugates for ADC (1) EGFR (2) ERK (1) Estrogen Receptor/ERR (3) FAK (1) Microtubule/Tubulin (3) Parasite (3) PGE synthase (1) STAT (1) TGF-β Receptor (1) TNF Receptor (1)
By Research Areas:	Cancer (32) Infection (1) Inflammation/Immunology (5)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: TAM Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119039

RU-301 1 Publications Verification	TAM Receptor	Inflammation/Immunology Cancer
RU-301 is a pan *TAM* inhibitor that blocks Gas6-induced *TAM* activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .

HY-116838

TAM-16	Bacterial	Infection
TAM-16 is a potent and orally active polyketide synthase 13 (Pks13) inhibitor with an IC₅₀ value of 0.32 μM. TAM-16 has promising activity against Mycobacterium tuberculosis. TAM-16 inhibits hERG cardiac ion channel .

HY-48564

TAM558 intermediate-5	ADC Cytotoxin	Cancer
TAM558 intermediate-54 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .

HY-126216

TAM-IN-2	TAM Receptor	Cancer
TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904 .

HY-157422

CSF1R-IN-19	c-Fms	Cancer
CSF1R-IN-19 is a potent inhibitor of CSF1R. CSF1R-IN-19 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-19 has the potential for the research of cancer .

HY-400690

TAM558 intermediate-4	Drug Intermediate	Cancer
TAM558 intermediate-4 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .

HY-400688

TAM558 intermediate-2	ADC Cytotoxin	Cancer
TAM558 intermediate-24 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .

HY-400687

TAM558 intermediate-1	Drug Intermediate	Cancer
TAM558 intermediate-1 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .

HY-400689

TAM558 intermediate-3	Drug Intermediate	Cancer
TAM558 intermediate-34 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .

HY-RS16320

TAM Human Pre-designed siRNA Set A
TAM Human Pre-designed siRNA Set A contains three designed siRNAs for TAM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAM Human Pre-designed siRNA Set A TAM Human Pre-designed siRNA Set A

HY-148127

TAM558	Drug-Linker Conjugates for ADC	Cancer
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .

HY-148128

TAM470	Microtubule/Tubulin ADC Cytotoxin	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-160473

TAM557	ADC Cytotoxin Microtubule/Tubulin	Cancer
TAM557 is a cytotoxic tubulysin compound that can be used in enzymatic conjugation reactions .

HY-128776

Antitumor agent-19	TNF Receptor	Cancer
Antitumor agent-19 is an antitumor agent that targets tumor-associated macrophages (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC₅₀ values???of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively .

HY-124066

RU-302	TAM Receptor	Cancer
RU-302 is a pan *TAM* inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC₅₀in cell assays, and suppresses lung cancer tumor growth .

HY-18719B

Endoxifen hydrochloride 1 Publications Verification	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .

HY-18719E

Endoxifen 1 Publications Verification	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .

HY-168954

CSF1R-IN-26	c-Fms Apoptosis Akt ERK STAT	Inflammation/Immunology Cancer
CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC₅₀ of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .

HY-163642

TNF-α agonistic 1	Others	Cancer
TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .

HY-160473A

TAM557 TFA	Microtubule/Tubulin	Cancer
TAM557 TFA is a cytotoxic tubulysin compounds, which is modified to be used for conjugation to transport vehicles that are targeting molecules, such as proteins, peptides, small molecules or polymeric carriers which can carry a targeting principle .

HY-117008

CAY10589	PGE synthase	Inflammation/Immunology
CAY10589 is an inhibitor of mPGES-1, an enzyme induced during inflammatory responses. CAY10589 has no significant effect on the differentiation of BM myeloid precursor cells into M2-like TAMs .

HY-12494

LDC1267 5+ Cited Publications	TAM Receptor	Inflammation/Immunology Cancer
LDC1267 is a highly selective TAM (Tyro3, Axl and Mer) kinase inhibitor with IC₅₀s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively .

HY-147218

PF-07265807	c-Met/HGFR TAM Receptor	Cancer
PF-07265807 is a potent *TAM* and c-Met kinase inhibitor with IC₅₀ values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer .

HY-18719ES

Endoxifen-d5	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-169517

Protein kinase inhibitor 10	TAM Receptor FAK c-Kit	Cancer
Protein kinase inhibitor 10 is a protein kinase inhibitor with IC₅₀ values of 28.9, 13.6, and 2.41 μM for TAM receptor, FAK, and KIT, respectively. Protein kinase inhibitor 10 can inhibit abnormal and excessive cell proliferation, showing promise for research in cancer therapy .

HY-P99746

Murlentamab 3C23K; GM102	TGF-β Receptor	Inflammation/Immunology Cancer
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .

HY-117548

UNC1062 1 Publications Verification	TAM Receptor	Cancer
UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. UNC1062 potently inhibits MERTK kinase activity (MERTK IC₅₀=1.1 nM, Morrison K_i=0.33 nM) and exhibits specificity within the TAM family (TYRO3 IC₅₀=60 nM, AXL IC₅₀=85 nM) .

HY-144041

CSF1R-IN-5	c-Fms	Cancer
CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .

HY-144040

CSF1R-IN-4	c-Fms	Cancer
CSF1R-IN-4 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104) .

HY-144042

CSF1R-IN-6	c-Fms	Cancer
CSF1R-IN-6 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5) .

HY-50895B

Gefitinib dihydrochloride ZD 1839 dihydrochloride	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD 1839) dihydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib dihydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib dihydrochloride also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .

HY-50895

Gefitinib Maximum Cited Publications 144 Publications Verification ZD1839	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .

HY-162415

CSF1R-IN-22	c-Fms Apoptosis	Cancer
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC₅₀<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 ⁺ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 ⁺ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .

Cat. No.	Product Name	Target	Research Area

HY-P10449

M2 Peptide	Peptides	Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

Cat. No.	Product Name	Target	Research Area

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-P99746

Murlentamab 3C23K; GM102	TGF-β Receptor	Inflammation/Immunology Cancer
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .

Endoxifen-d5
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

TAM Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
TAM Human Pre-designed siRNA Set A contains three designed siRNAs for TAM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: